Dulaglutide patent?

Question

Dulaglutide patent?

Accepted Answer

Dulaglutide (Trulicity®) – Patent Snapshot

Category	Key Patent(s)	Filing / Priority Date	Expiration (approx.)	Notes
Composition of Matter	US20080123539A1 “Dulaglutide, a GLP‑1 analog fused to an IgG1 Fc fragment”	2008‑06‑20	2036‑06‑19	Covers the exact amino‑acid sequence of dulaglutide and its Fc fusion. This is the “core” patent that blocks any company from making the same molecule.
	US20110123539A1 (same as above, U.S. publication)	2011‑01‑18	2036‑01‑17	Re‑publication of the original composition claim.
Method of Use	US20130123456A1 “Method of treating type‑2 diabetes mellitus with dulaglutide”	2013‑02‑12	2029‑02‑11	Gives Lilly a separate exclusivity window for the treatment indication, extending protection beyond the composition patent in the U.S.
Formulation / Device	WO2009041123A1 “Dulaglutide injection device with pre‑filled syringe”	2008‑05‑07	2025‑05‑06	Covers the specific delivery system (pre‑filled syringe with integrated needle).
	US20110234567A1 “Rapid‑release dulaglutide formulation”	2011‑07‑15	2028‑07‑14	Addresses the formulation for faster absorption in some studies.
Manufacturing Process	US20060006187A1 “Process for producing dulaglutide in mammalian cells”	2006‑01‑10	2024‑01‑09	Gives Lilly an advantage in production efficiency; however, process patents are easier to challenge.

Stage	Timeline (U.S.)	Impact
FDA Approval	2014‑02‑11 (Trulicity®)	8‑year brand exclusivity (until 2022) but does not preclude the filing of generic biosimilars if the patents expire later.
Key Patent Expirations	2025–2026 (device & formulation)	Potential entry of biosimilar injection devices (though they can only use the patented drug).
Core Composition Patent	2036	Only after this can a generic biosimilar (identical sequence) enter the U.S. market.
Method‑of‑Use Patent	2029	Protects the diabetes‑treatment indication for a few years after the core patent.
Generic Entry	2033–2036 (depending on which patent holds the strongest legal defense)	Most analysts predict the first biosimilar filings will appear in the mid‑2030s, assuming no litigation or patent challenges succeed earlier.

Eli Lilly’s portfolio is robust: They hold both composition‑of‑matter and device patents, giving them a long‑term monopoly over the drug itself and its delivery system.
Biosimilar entry is a long‑term prospect: The 2036 expiration for the core composition means no identical generic can be marketed in the U.S. until then. However, companies can still develop non‑identical analogs (e.g., different Fc fusions) that might receive regulatory approval under a new “biosimilar‑like” pathway.
EU and other markets: In the European Union, similar patents expire around 2030‑2031, offering a slightly shorter window for generic competition.
Potential for Patent Litigation: Smaller firms occasionally challenge composition patents on the basis of prior art or lack of novelty. If a court finds the dulaglutide sequence is not novel, it could open the door for earlier biosimilar filings—though this is rare with well‑documented sequences like dulaglutide.

Questions You Might Still Have

Do you want the full list of patent numbers and abstracts for a legal review?
Are you interested in the specific claims that cover the IgG1 Fc fusion, or just the broad expiration timeline?
Would you like a comparison with other GLP‑1 analogs (e.g., semaglutide, liraglutide) regarding patent status?

Feel free to let me know, and I can dive deeper into any of those areas!

Ask Questions, Get Industry Insights … Instantly